Anixa Biosciences, Inc. (ANIX) Completes 5th CAR‑T Cohort; No DLTs, Stable Disease Seen

Anixa Biosciences completed dosing for the fifth cohort in its Phase 1 CAR-T trial for ovarian cancer, reporting no dose-limiting toxicities and stable disease in the first patient. Four patients have survived over a year, one over two years. The trial is in early-stage safety and dose-escalation, with preliminary efficacy signals.

Original reporting
Published Oct 26, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anixa Biosciences, Inc. (ANIX) Completes 5th CAR‑T Cohort; No DLTs, Stable Disease Seen — source image
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The absence of dose‑limiting toxicities and stable disease signals a favorable safety profile, potentially supporting the stock.

02

Market read

Positive Phase 1 safety update may attract speculative interest in a micro‑cap biotech.

03

What to watch

No efficacy data yet; investors should watch for response rates in higher doses.

Relevance 7/10Novelty 7/10Timing: today

Background

Anixa Biosciences is a clinical‑stage biotech developing FSHR‑targeted CAR‑T therapies for ovarian cancer.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Anixa completed dosing of the fifth CAR‑T cohort, reporting no dose‑limiting toxicities and stable disease at 90 days.

Expected impact

likely modest upside as market prices in the favorable safety profile

Evidence & confidence

Phase 1 safety readouts are early but positive results often lift micro‑cap biotech stocks.

Market effects

May boost sentiment for CAR‑T and broader cell‑therapy sector.

Limited to US biotech investors.

Minimal, confined to niche biotech community.

Counterpoint

Early‑stage data may be over‑interpreted; later cohorts could reveal safety issues.

Key entities

  • Anixa Biosciences, Inc.

    Developer of the CAR‑T therapy.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.

$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.